


Specification**Claims****Claim 1**

A compound represented by the following Chemical Formula 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

[Formula 1]



in Formula 1,

n is 0, 1, 2, 3, 4 or 5,

R₁, R₂, and R₃ are each independently the same as or different from each other, and are each independently selected from hydrogen, a C₁₋₇ alkyl, a C₃₋₆ cycloalkyl, hydroxyl, a halogen, a halogenated C₁₋₇ alkyl, a C₁₋₇ alkoxy and a halogenated C₁₋₇ alkoxy, and

X is m substituents (m is an integer from 1 to 5) which are the same as or different from each other, selected from the group consisting of a halogen group, a halogenated C₁₋₇ alkyl group and a halogenated C₁₋₇ alkoxy group.

Claim 2

The compound, the stereoisomer thereof, or the pharmaceutically acceptable salt thereof of claim 1, wherein R₁ and R₂ are each independently H or methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, cyclobutyl, n-pentyl, cyclopentyl, n-hexyl or cyclohexyl, and R₃ is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.

Claim 3

The compound, the stereoisomer thereof, or the pharmaceutically acceptable salt thereof of claim 1, wherein X is any one or two identical or different substituents selected from the group consisting of fluoro, chloro, trifluoromethyl and trifluoromethoxy.

Claim 4

The compound, the stereoisomer thereof, or the pharmaceutically acceptable salt thereof of claim 3, wherein X is p-fluoro, m-fluoro, p,m-difluoro, p-chloro, m-chloro, p,m-dichloro, p-trifluoromethyl or p-trifluoromethoxy.

Claim 5

The compound, the stereoisomer thereof, or the pharmaceutically acceptable salt thereof of claim 1, wherein the compound is

- 1) 2-amino-N-(3',4'-dichloro-[1,1'-biphenyl]-4-yl)butanamide;
- 2) 2-amino-N-(3',4'-dichloro-[1,1'-biphenyl]-4-yl)pentanamide;
- 3) 2-amino-N-(3',4'-dichloro-[1,1'-biphenyl]-4-yl)hexanamide;
- 4) 2-amino-N-(4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)pentanamide;
- 5) N-(3',4'-dichloro-[1,1'-biphenyl]-4-yl)-2-(methylamino)butanamide;
- 6) N-(3',4'-dichloro-[1,1'-biphenyl]-4-yl)-2-(methylamino)pentanamide;
- 7) N-(3',4'-dichloro-[1,1'-biphenyl]-4-yl)-2-(methylamino)hexanamide;
- 8) N-(3',4'-dichloro-[1,1'-biphenyl]-4-yl)-2-(dimethylamino)pentanamide;
- 9) 2-amino-N-((3',4'-dichloro-[1,1'-biphenyl]-4-yl)methyl)pentanamide;
- 10) 2-amino-N-((3',4'-dichloro-[1,1'-biphenyl]-4-yl)methyl)hexanamide;
- 11) 2-amino-N-((4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)methyl)pentanamide;
- 12) 2-amino-N-((4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)methyl)hexanamide;
- 13) 2-amino-N-((4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)methyl)pentanamide;
- 14) 2-amino-N-((4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)methyl)hexanamide;

- 15) N-((3',4'-dichloro-[1,1'-biphenyl]-4-yl)methyl)-2-(methylamino)pentanamide;
- 16) 2-(methylamino)-N-((4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)methyl)pentanamide;
- 17) N-((3',4'-dichloro-[1,1'-biphenyl]-4-yl)methyl)-2-(dimethylamino)pentanamide;
- 18) 2-amino-N-(2-(3',4'-dichloro-[1,1'-biphenyl]-4-yl)ethyl)butanamide;
- 19) 2-amino-N-(2-(3',4'-dichloro-[1,1'-biphenyl]-4-yl)ethyl)pentanamide;
- 20) 2-amino-N-(2-(3',4'-dichloro-[1,1'-biphenyl]-4-yl)ethyl)hexanamide;
- 21) 2-amino-N-(2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)ethyl)butanamide;
- 22) 2-amino-N-(2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)ethyl)pentanamide;
- 23) 2-amino-N-(2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)ethyl)hexanamide;
- 24) 2-amino-N-(2-(4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)ethyl)butanamide;
- 25) 2-amino-N-(2-(4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)ethyl)pentanamide;
- 26) 2-amino-N-(2-(4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)ethyl)hexanamide;
- 27) 2-amino-N-(2-(3',4'-difluoro-[1,1'-biphenyl]-4-yl)ethyl)pentanamide;
- 28) N-(2-(3',4'-dichloro-[1,1'-biphenyl]-4-yl)ethyl)-2-(methylamino)butanamide;
- 29) N-(2-(3',4'-dichloro-[1,1'-biphenyl]-4-yl)ethyl)-2-(methylamino)pentanamide;
- 30) N-(2-(3',4'-dichloro-[1,1'-biphenyl]-4-yl)ethyl)-2-(methylamino)hexanamide;
- 31) 2-(methylamino)-N-(2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)ethyl)butanamide;
- 32) 2-(methylamino)-N-(2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)ethyl)pentanamide;
- 33) 2-(methylamino)-N-(2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)ethyl)hexanamide;
- 34) 2-(methylamino)-N-(2-(4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)ethyl)butanamide;
- 35) 2-(methylamino)-N-(2-(4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)ethyl)pentanamide;
- 36) 2-(methylamino)-N-(2-(4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)ethyl)hexanamide; or
- 37) N-(2-(3',4'-dichloro-[1,1'-biphenyl]-4-yl)ethyl)-2-(dimethylamino)pentanamide.


Claim 6

A method for preparing the compound, the stereoisomer thereof, or the pharmaceutically


acceptable salt thereof of any one of claims 1 to 5, the method comprising a first step of forming a peptide bond by reacting an aminoalkanoic acid derivative compound protected by a butoxycarbonyl (Boc) protecting group, which is represented by the following Formula 2, with a biphenyl derivative compound containing a primary amine group, which is represented by the following Formula 3; and

a second step of removing the Boc protecting group by reacting the compound obtained in the first step with an acid:


[Formula 1]



[Formula 2]



[Formula 3]



in the formulae,

n is 0, 1, 2, 3, 4 or 5,

R₁, R₂ and R₃ are each independently the same as or different from each other, and are each independently selected from hydrogen, a C₁₋₇ alkyl, hydroxyl, a halogen, a halogenated C₁₋₇


alkyl, a C₁₋₇ alkyloxy and a halogenated C₁₋₇ alkyloxy, and

X is m substituents (m is an integer from 1 to 5) which are the same as or different from each other, selected from the group consisting of a halogen group, a halogenated C₁₋₇ alkyl group and a halogenated C₁₋₇ alkoxy group.

Claim 7

The method of claim 6, wherein the aminoalkanoic acid derivative compound protected by the Boc protecting group, which is represented by Formula 2 is prepared by reacting an amino acid derivative represented by the following Formula 4 with di-tert-butyl dicarbonate (Boc anhydride):

[Formula 4]



in the formula,

R_{1'}, R₂ and R₃ are each independently the same as or different from each other, and are each independently selected from hydrogen, a C₁₋₇ alkyl, hydroxyl, a halogen, a halogenated C₁₋₇ alkyl, a C₁₋₇ alkyloxy and a halogenated C₁₋₇ alkyloxy.

Claim 8


The method of claim 7, wherein when R₂ of the finally prepared compound is an alkyl, a step of alkylating the compound by reacting the compound with a haloalkane in the presence of a base after the above reaction is further performed.

Claim 9


The method of claim 6, wherein a biphenyl derivative compound comprising a primary amine group, which is represented by Formula 3 is prepared by reacting a C₀₋₂ alkylamine derivative in which a halophenyl group at one end is substituted, which is represented by the following

Formula 5, with di-tert-butyl dicarbonate to introduce a Boc protecting group into an amine group, then reacting the resulting alkylamine derivative with a phenylboronic acid derivative represented by the following Formula 6, and then reacting the reactants with an acid to remove the Boc protecting group:

[Formula 5]



[Formula 6]



in the formulae,

X' is a halogen, and

X is m substituents (m is an integer from 1 to 5) which are the same as or different from each other, selected from the group consisting of a halogen group, a halogenated C₁₋₇ alkyl group and a halogenated C₁₋₇ alkoxy group.

Claim 10

The method of claim 9, wherein the reaction with the phenylboronic acid derivative is achieved by a cross-coupling reaction using a metal catalyst in the presence of a base.

Claim 11

The method of claim 6, wherein the first step is achieved by an anhydride coupling reaction performed in an organic solvent in the presence of N-methylmorpholine (NMM) and isobutyl chloroformate (IBCF).

Claim 12

The method of claim 6, further comprising a third step of forming a secondary amine by alkylating amine after the second step when both R₁ and R₂ of the compound finally prepared are an alkyl.

Claim 13

An antifungal composition comprising, as an active ingredient, the compound, the stereoisomer thereof, or the pharmaceutically acceptable salt thereof of any one of claims 1 to 5.

Claim 14

The antifungal composition of claim 13, wherein the antifungal composition exhibits antifungal activity against *Cryptococcus neoformans*, *Candida albicans*, *Candida glabrata*, or *Aspergillus fumigatus*.

Claim 15

A pharmaceutical composition for treating or preventing a fungal infectious disease, comprising, as an active ingredient, the compound, the stereoisomer thereof, or the pharmaceutically acceptable salt thereof of any one of claims 1 to 5.

Claim 16

The pharmaceutical composition of claim 15, wherein the fungal infectious disease is caused by infections of *Cryptococcus neoformans*, *Candida albicans*, *Candida glabrata*, or *Aspergillus fumigatus*.

Claim 17

The pharmaceutical composition of claim 15, further comprising a pharmaceutically acceptable carrier, diluent or excipient.

Claim 18

An antibacterial composition comprising, as an active ingredient, the compound, the stereoisomer thereof, or the pharmaceutically acceptable salt thereof of any one of claims 1 to 5.

Claim 19

The antibacterial composition of claim 18, wherein the antibacterial composition exhibits antibacterial activity against Gram-negative bacteria, Gram-positive bacteria, or multi-drug resistant bacteria.

Claim 20

A pharmaceutical composition for treating or preventing a bacterial infectious disease, comprising, as an active ingredient, the compound, the stereoisomer thereof, or the pharmaceutically acceptable salt thereof of any one of claims 1 to 5.

Claim 21

A pharmaceutical composition for treating or preventing an anti-inflammatory disease, comprising the compound, the stereoisomer thereof, or the pharmaceutically acceptable salt thereof of any one of claims 1 to 5, and a pharmaceutically acceptable carrier, diluent or excipient.